Argos announced the initiation of a Phase 2b study of Arcelis (AGS-004), its personalized immunotherapy for the treatment of HIV patients. This trial is a multicenter, randomized, double-blind, placebo-controlled study in HIV infected patients receiving antiretroviral therapy (ART) to evaluate the efficacy and safety of AGS-004 when compared to placebo during an analytical treatment interruption of ART. The trial’s primary objective is to compare AGS-004 with placebo and the anti-HIV effects of AGS-004 as measured by the new plasma HIV viral load set point established at the end of the 12 week analytical treatment interruption.
Arcelis is a personalized, RNA-loaded, dendritic cell-based immunotherapy that uses Argos’ proprietary technology to be perfectly matched to each patient’s unique HIV viral burden.
For more information call (919) 287-6300 or visit www.argostherapeutics.com.